U106
(−)-cis-(1S,2R)-U-50488 tartrate
solid
Synonym(s):
(−)-(1S,2R)-cis-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide tartrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H26Cl2N2O · C4H6O6
CAS Number:
Molecular Weight:
519.42
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
form
solid
color
white
solubility
ethanol: soluble
storage temp.
2-8°C
SMILES string
OC(C(O)C(O)=O)C(O)=O.CN([C@H]1CCCC[C@H]1N2CCCC2)C(=O)Cc3ccc(Cl)c(Cl)c3
InChI
1S/C19H26Cl2N2O.C4H6O6/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23;5-1(3(7)8)2(6)4(9)10/h8-9,12,17-18H,2-7,10-11,13H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t17-,18+;/m0./s1
InChI key
DMBKHRMAGYYBJM-CJRXIRLBSA-N
Gene Information
human ... OPRS1(10280)
Biochem/physiol Actions
Potent σ receptor ligand.
Preparation Note
(-)-cis-(1S,2R)-U-50488 tartrate is soluble in ethanol.
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A A Spasov et al.
Eksperimental'naia i klinicheskaia farmakologiia, 74(8), 45-47 (2012-01-12)
A new model is proposed for in vitro testing the efficiency of new chemical substances with kappa-opioid receptor agonist ligand properties.
Amber D Shaffer et al.
Neuroscience letters, 534, 150-154 (2012-12-04)
Previous research has suggested that early-in-life (EIL) exposure to bladder inflammation impairs the function of endogenous opioid inhibitory system(s) and may contribute to the development of chronic bladder pain. This study examined how acute adult and/or prior EIL exposure to
Thiago M Cunha et al.
Molecular pain, 8, 10-10 (2012-02-10)
In addition to their central effects, opioids cause peripheral analgesia. There is evidence showing that peripheral activation of kappa opioid receptors (KORs) inhibits inflammatory pain. Moreover, peripheral μ-opioid receptor (MOR) activation are able to direct block PGE(2)-induced ongoing hyperalgesia However